Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

Inventiva named Jason Campagna as president of R&D and chief medical officer, and Martine Zimmermann as EVP of regulatory affairs and quality assurance. Evolent named Dr. David Lim as chief clinical ...

Kenvue Inc. closed 13.19% below its 52-week high of $25.17, which the company achieved on May 8th.

Kenvue, which was spun off from Johnson & Johnson in 2023, has been working to shore up profitability, especially in its ...

Johnson & Johnson reported second-quarter results on July 16. Sales of pharmaceuticals have been muted due to a loss of ...

Experts are raising concerns about Benadryl’s ability to cross the blood-brain barrier and potential lasting impacts.

After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Johnson & Johnson stands alone as a leader across the major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that ...

Detailed price information for E.L.F. Beauty Inc (ELF-N) from The Globe and Mail including charting and trades.

Johnson & Johnson ( NYSE: JNJ) Q2 2025 Earnings Conference Call July 16, 2025 8:30 AM ET ...

JNJ tops second-quarter estimates and raises 2025 guidance as Innovative Medicines outperforms and MedTech gains momentum.